• In late February 2026, Recursion Pharmaceuticals reported fourth-quarter 2025 revenue of US$35.54 million with a quarterly net loss of US$108.12 million, and around the same time filed a US$300 million at-the-market follow-on equity offering plus a US$68.57 million shelf registration tied to an ESOP.
• Shortly after these filings, Director Blake Borgeson sold 170,000 Class A shares while still retaining more than 6.25 million shares, drawing attention to insider sentiment alongside the company’s ongoing funding needs.
• We’ll now examine how the recent insider sale and fresh US$300 million at-the-market equity program affect Recursion’s investment narrative.

Capitalize on the AI infrastructure supercycle with our selection of the 35 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

Recursion Pharmaceuticals Investment Narrative Recap

To own Recursion Pharmaceuticals, you have to believe its AI-driven Recursion OS can convert today’s heavy R&D spend into tomorrow’s clinically meaningful drugs and partnerships. Near term, the key catalyst is progress toward a registration path for REC‑4881 in FAP, while the biggest risk is continued cash burn and funding needs. The new US$300 million at-the-market program and insider sale highlight dilution and financing risk but do not directly change the core clinical catalyst.

Among the latest announcements, the US$300 million at-the-market offering is most relevant here because it sits at the intersection of Recursion’s funding needs and insider sentiment. It reinforces that advancing REC‑4881 and the broader pipeline will likely require substantial external capital, especially after a 2025 net loss of US$644.76 million, and that any share price reaction to upcoming FAP or partnership updates will now play directly into how efficiently the company can raise that cash.

Yet behind the promise of AI-enabled drug discovery, investors should be aware that dilution risk and Recursion’s dependence on external capital could...

Recursion Pharmaceuticals’ narrative projects $220.9 million revenue and $35.5 million earnings by 2028.

Uncover how Recursion Pharmaceuticals' forecasts yield a $7.00 fair value, a 98% upside to its current price.

Exploring Other Perspectives

Before this earnings and equity raise news, the most optimistic analysts were assuming revenue could reach about US$404 million by 2028, but if Recursion falls short on key partnership milestones or FAP progress, that far more upbeat view could diverge sharply from how you see the story unfolding.

Explore 6 other fair value estimates on Recursion Pharmaceuticals - why the stock might be worth 44% less than the current price!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Recursion Pharmaceuticals research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Recursion Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Recursion Pharmaceuticals' overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• Explore 22 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• Rare earth metals are the new gold rush. Find out which 29 stocks are leading the charge.
• We've uncovered the 14 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.